In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Congenital infection with human cytomegalovirus is a major cause of morbidity and mortality. A randomized controlled trial showed that high-dosage valacyclovir prevents cytomegalovirus disease in transplant recipients. Fetuses showing ultrasound features of infection are at high risk of being symptomatic at or before birth. In a pilot study, oral administration of high-dosage valacyclovir to mothers significantly decreased viral load and produced therapeutic concentrations in the blood of infected fetuses. A randomized controlled trial comparing prenatal treatment with valacyclovir against placebo in infected fetuses failed to recruit because women declined randomization. Randomized controlled trials in fetal medicine have often proven unacceptable by women who decline termination of pregnancy and are not prepared to resign themselves to the odds of the natural history of the disease. OBJECTIVE: We evaluated the efficacy of oral valacyclovir, 8 g daily, for pregnant women carrying a symptomatic cytomegalovirus-infected fetus, targeting a high-risk group for developing both neurosensory and neurological impairment. STUDY DESIGN: We designed a multicenter, open-label, phase II study with 1 arm, using one of Simon's optimal 2-stage designs. Symptomatic fetuses were defined by the presence of measurable extracerebral or mild cerebral ultrasound symptoms. They were treated in utero from prenatal diagnosis at a median of 25.9 weeks' gestation until delivery or termination of pregnancy. Fetuses with severe brain anomalies on ultrasound were not included as were cases completely asymptomatic at presentation, because treatment was unlikely to modify either outcome. The primary endpoint was the proportion of asymptomatic neonates born to treated mothers. RESULTS: At the interim analysis, 8 of 11 women delivered an asymptomatic neonate (required: ≥7). In step 2, 32 additional cases were included for a total of 43; the final number of asymptomatic neonates was 34, more than the 31 required to indicate efficacy according to the Simon 2-stage design. They remained asymptomatic at 12 months. High-dosage valacyclovir given for a median of 89 days to pregnant women carrying a moderately infected fetus was efficient at giving birth to asymptomatic neonates. Fetal blood viral loads decreased and platelet counts increased, both significantly (P = .01 and P < .001, respectively), between treatment initiation and birth after treatment completion, regardless of duration of fetal infection. Compared with a historical cohort obtained by a metaanalysis of the literature, the use of valacyclovir (8 g daily) significantly increased the proportion of asymptomatic neonates from 43% without treatment to 82% with treatment. Although the pill burden was high (16 pills a day) adherence to treatment was >90%. Finally, valacyclovir at this high dosage was extremely well tolerated. CONCLUSION: Our results indicate that high-dosage valacyclovir given in pregnancy is effective for improving the outcome of moderately symptomatic infected fetuses. Although this study is not a randomized controlled trial, this is the first study reporting the efficacy of an antiviral drug to treat cytomegalovirus-infected fetuses. Moreover, this first study will allow new trials to be conducted, using valacyclovir as a baseline safe and effective treatment in pregnancy, to be compared to the new emerging and more potent anticytomegalovirus drugs that have not currently been tested in pregnancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Estimation of fetal weight with the use of head, body, and femur measurements—A prospective study
Hadlock, F. P., Harrist, R. B., Sharman, R. S., Deter, R. L., & Park, S. K. (1985) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(85)90298-4 · Cited by 2,682
Review and meta‐analysis of the epidemiology of congenital cytomegalovirus (CMV) infection
Kenneson, A., & Cannon, M. J. (2007) · Reviews in Medical Virology · doi:10.1002/rmv.535 · Cited by 1,720 · cited 1×
“7% of live births and is the leading cause of congenital neurological disease of infectious origin.(1) Among all neonates positive for infection on screening, 20% eventually have neurodevelopmental impairment with permanent sequelae.”
BackgroundDollard, S. C., Grosse, S. D., & Ross, D. S. (2007) · Reviews in Medical Virology · doi:10.1002/rmv.544 · Cited by 1,257 · cited 2×
“Among all neonates positive for infection on screening, 20% eventually have neurodevelopmental impairment with permanent sequelae.(2) Around 10% of infected neonates are symptomatic at birth; their risk of sequelae reaches 58%, including sensorineural hearing loss or cognitive or motor defects.”
BackgroundValganciclovir for Symptomatic Congenital Cytomegalovirus Disease
Kimberlin, D. W., Jester, P. M., Sánchez, P. J., Ahmed, A., Arav-Boger, R., Michaels, M. G., Ashouri, N., Englund, J. A., Estrada, B., Jacobs, R. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1404599 · Cited by 827
Passive Immunization during Pregnancy for Congenital Cytomegalovirus Infection
Nigro, G., Adler, S. P., La Torre, R., & Best, A. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043337 · Cited by 784
Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal Transplantation
Lowance, D., Neumayer, H.-H., Legendre, C. M., Squifflet, J.-P., Kovarik, J., Brennan, P. J., Norman, D., Mendez, R., Keating, M. R., Coggon, G. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905133401903 · Cited by 712 · cited 2×
“Although valacyclovir is less effective than ganciclovir against CMV in vitro,(15) high-dosage valacyclovir has proven clinically efficient to prevent CMV disease in transplant recipients.(16) The mechanism of acyclovir’s anti-CMV activity in clinical settings remains unexplained.”
BackgroundRelton, C., Torgerson, D., O'Cathain, A., & Nicholl, J. (2010) · BMJ · doi:10.1136/bmj.c1066 · Cited by 518
A Randomized Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus
Revello, M. G., Lazzarotto, T., Guerra, B., Spinillo, A., Ferrazzi, E., Kustermann, A., Guaschino, S., Vergani, P., Todros, T., Frusca, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310214 · Cited by 489 · cited 1×
“The use of CMV-specific hyperimmune globulin to prevent transmission from mother to fetus has produced conflicting results.(12,13) Neonatal antiviral treatment with either ganciclovir or valganciclovir improves auditory and neurological outcomes in symptomatic newborns,(14) but these drugs, highly genotoxic in vitro,…”
BackgroundLIESNARD, C. (2000) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(99)00657-2 · Cited by 270
Cited by
Rawlinson, W. D., Boppana, S. B., Fowler, K. B., Kimberlin, D. W., Lazzarotto, T., Alain, S., Daly, K., Doutré, S., Gibson, L., Giles, M. L., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30143-3 · Cited by 841
Chatzakis, C., Ville, Y., Makrydimas, G., Dinas, K., Zavlanos, A., & Sotiriadis, A. (2020) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.05.038 · Cited by 229
Self-citation
Metadata
- Authors
- Leruez-Ville, M., Ghout, I., Bussières, L., Stirnemann, J., Magny, J.-F., Couderc, S., Salomon, L. J., Guilleminot, T., Aegerter, P., Benoist, G., Winer, N., Picone, O., Jacquemard, F., & Ville, Y.
- Venue
- American Journal of Obstetrics and Gynecology
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 215
- Issue
- 4
- Pages
- 462.e1-462.e10
- ISSN
- 0002-9378 (ISSN-L)
- OpenAlex
- W2341411355
- Cited by
- 239
- References
- 33
- FWCI
- 16.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study. https://app.cochat.ai/papers/10.1016/j.ajog.2016.04.003
- The paper
- Leruez-Ville, M., Ghout, I., Bussières, L., Stirnemann, J., Magny, J.-F., Couderc, S., Salomon, L. J., Guilleminot, T., Aegerter, P., Benoist, G., Winer, N., Picone, O., Jacquemard, F., & Ville, Y. (2016). In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study. American Journal of Obstetrics and Gynecology. https://doi.org/10.1016/j.ajog.2016.04.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.